Press Releases

BioMS Medical Presents at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis

Edmonton, Alberta, October 15, 2007 – BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that interim safety observations from MAESTRO-01, the Company’s on-going phase III trial of MBP8298 for the treatment of secondary progressive MS, were reported in a poster presentation at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Prague, Czech Republic. A second poster presentation reported the percentage of patients screened for the trial that had the target HLA-DR2/DR4 immune response genes.

ECTRIMS is one of the largest and most prestigious annual MS conferences, bringing together MS experts and thought leaders from around the world to discuss the latest MS research findings.

The first poster, entitled “Safety observations from administration of MBP8298 as part of the ongoing phase III MAESTRO-01 secondary progressive MS clinical trial”, showed that MBP8298 administration resulted in no significant safety concerns measured over the current course of the MAESTRO-01 study.

The second poster, entitled “Haplotype analysis of Secondary Progressive Patients participating in the MAESTRO-01 Study”, showed that overall, amongst the 10 countries enrolling patients in the MAESTRO-01 trial, (Canada, United Kingdom, Finland, Denmark, Sweden, Estonia, Latvia, Spain, Germany and the Netherlands) 70.38% of the 788 screened patients were observed to have HLA-DR2 and/or HLA-DR4 immune response genes.

"The first poster presentation demonstrates that the safety profile of our drug continues to look strong in a large multinational clinical trial setting," said Kevin Giese, President and CEO of BioMS. "The second poster reaffirms that MS patients with HLA-DR2/DR4 immune response genes, potentially account for more than 70% of the overall MS population in Europe and Canada."

About MBP8298 - Novel Mechanism of Action

In MS patients, the body's immune system inappropriately attacks the myelin coating around the nerves in the brain and spinal column, whereas healthy people are “tolerant” of such normal body components. The proposed mechanism of action of MBP8298 is, by design, to re-introduce such a state of “tolerance” to a critical portion of the nerve's Myelin Basic Protein that is an immunological site of attack in many MS patients. This is accomplished by the I.V. injection of MBP8298 every six months.
Phase II and long-term follow-up treatment of MS patients with MBP8298, recently published in the European Journal of Neurology showed that MBP8298 safely delayed the median time to disease progression for five years in progressive MS patients with HLA-DR2 or HLA-DR4 immune response genes.
MBP8298 is being developed in three late-stage clinical trials:

• MAESTRO-01: A pivotal phase III trial in Canada and Western Europe evaluating MBP8298 for the treatment of secondary progressive multiple sclerosis (SPMS). The trial is a randomized, double-blind study and is fully recruited with 611 patients.
• MAESTRO-03: A pivotal phase III U.S. trial evaluating MBP8298 for the treatment of SPMS. The trial is a randomized, double-blind study enrolling approximately 510 patients.
• MINDSET-01: A phase II trial evaluating MBP8298 for the treatment of relapsing remitting multiple sclerosis (RRMS). The trial is a randomized, double-blind study and is fully recruited with 218 patients.

This press release may contain forward-looking statements, which reflect the Corporation’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Corporation’s ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide (MBP8298) will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.